Page last updated: 2024-11-06

11-bromovincamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

11-bromovincamine is a synthetic derivative of vincamine, an alkaloid extracted from the Madagascar periwinkle plant (Catharanthus roseus). It was developed as a potential therapeutic agent for the treatment of cognitive impairment, particularly in the context of cerebrovascular diseases. 11-bromovincamine has been shown to exhibit vasodilatory effects, improving blood flow in the brain. It is believed to act by enhancing the release of nitric oxide (NO), a potent vasodilator, and by inhibiting the reuptake of dopamine, a neurotransmitter involved in cognitive function. Studies have suggested that 11-bromovincamine may improve cognitive performance in patients with mild cognitive impairment and Alzheimer's disease. However, its therapeutic efficacy remains under investigation, and further research is needed to establish its clinical utility. 11-bromovincamine is also being explored for its potential anti-inflammatory and neuroprotective properties.'

11-bromovincamine: RN given refers to (3alpha,14beta,16alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68771
CHEMBL ID165643
CHEBI ID135701
SCHEMBL ID564244
MeSH IDM0104121

Synonyms (26)

Synonym
sarbromin (tn)
brovincamine (inn)
57475-17-9
D07545
brovincamina [inn-spanish]
11-bromovincamine
brovincamine
brovincaminum [inn-latin]
brovincamine [inn]
bv 26-723
9-bromvincamin
CHEBI:135701
CHEMBL165643
sarbromin
brovincamina
ayn5t18k5r ,
brovincaminum
unii-ayn5t18k5r
SCHEMBL564244
brovincamine [mi]
brovincamine [who-dd]
WYIJGAVIVKPUGJ-GIVPXCGWSA-N
11-bromovincamine; 11-brovincamine
Q27274193
methyl (15s,17s,19s)-4-bromo-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraene-17-carboxylate
DTXSID701024133

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"/ml) at 1 h after dosing and declined biphasically with half-lives of 5 h and 11 h which were similar to half-lives for urinary excretion of 3H."( The metabolic fate of 11-bromo[15-3H]vincamine in man.
Biggs, SR; Chasseaud, LF; Darragh, A; Hawkins, DR; Leaf, FC; Mayo, BC,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID60591Effect on femoral blood flow (FBF) was studied, after intra arterial administration in anesthetized dogs relative to vinpocetine1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and pharmacological evaluation of (nitrooxy)alkyl apovincaminates.
AID60592Effect on vertebral blood flow (VBF) was studied, after intra arterial administration in anesthetized dogs relative to vinpocetine1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Synthesis and pharmacological evaluation of (nitrooxy)alkyl apovincaminates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (52.38)18.7374
1990's8 (38.10)18.2507
2000's2 (9.52)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.80 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]